Susquehanna International Group’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-57,400
| Closed | -$226K | – | 14210 |
|
|
2025
Q4 | $226K | Buy |
57,400
+17,100
| +42% | +$75.6K | ﹤0.01% | 10604 |
|
|
2025
Q3 | $188K | Buy |
40,300
+28,300
| +236% | +$102K | ﹤0.01% | 11057 |
|
|
2025
Q2 | $37.3K | Buy |
+12,000
| New | +$38.7K | ﹤0.01% | 12191 |
|
|
2024
Q4 | – | Sell |
-34,100
| Closed | -$199K | – | 13353 |
|
|
2024
Q3 | $199K | Sell |
34,100
-1,400
| -4% | -$10.2K | ﹤0.01% | 10473 |
|
|
2024
Q2 | $281K | Buy |
35,500
+11,000
| +45% | +$92.2K | ﹤0.01% | 9602 |
|
|
2024
Q1 | $228K | Sell |
24,500
-14,300
| -37% | -$121K | ﹤0.01% | 10320 |
|
|
2023
Q4 | $327K | Buy |
38,800
+700
| +2% | +$5.08K | ﹤0.01% | 9641 |
|
|
2023
Q3 | $295K | Sell |
38,100
-18,300
| -32% | -$167K | ﹤0.01% | 9379 |
|
|
2023
Q2 | $646K | Sell |
56,400
-34,400
| -38% | -$356K | ﹤0.01% | 7712 |
|
|
2023
Q1 | $700K | Buy |
90,800
+25,300
| +39% | +$201K | ﹤0.01% | 7724 |
|
|
2022
Q4 | $400K | Sell |
65,500
-122,300
| -65% | -$695K | ﹤0.01% | 8393 |
|
|
2022
Q3 | $1.11M | Buy |
187,800
+7,300
| +4% | +$46.7K | ﹤0.01% | 6357 |
|
|
2022
Q2 | $1.07M | Sell |
180,500
-99,400
| -36% | -$671K | ﹤0.01% | 6370 |
|
|
2022
Q1 | $2.13M | Buy |
279,900
+99,500
| +55% | +$444K | ﹤0.01% | 5337 |
|
|
2021
Q4 | $489K | Buy |
+180,400
| New | +$616K | ﹤0.01% | 9277 |
|
|
2021
Q3 | – | Sell |
-62,400
| Closed | -$258K | – | 13666 |
|
|
2021
Q2 | $258K | Buy |
+62,400
| New | +$283K | ﹤0.01% | 11083 |
|
|
2020
Q4 | – | Sell |
-15,900
| Closed | -$170K | – | 11802 |
|
|
2020
Q3 | $170K | Sell |
15,900
-100
| -0.6% | -$1.17K | ﹤0.01% | 9600 |
|
|
2020
Q2 | $202K | Buy |
+16,000
| New | +$186K | ﹤0.01% | 9028 |
|
|
2020
Q1 | – | Sell |
-31,500
| Closed | -$439K | – | 10966 |
|
|
2019
Q4 | $439K | Sell |
31,500
-21,400
| -40% | -$311K | ﹤0.01% | 7242 |
|
|
2019
Q3 | $910K | Sell |
52,900
-46,000
| -47% | -$966K | ﹤0.01% | 5880 |
|
|
2019
Q2 | $2.69M | Buy |
98,900
+35,600
| +56% | +$815K | ﹤0.01% | 3637 |
|
|
2019
Q1 | $1.21M | Buy |
63,300
+38,400
| +154% | +$500K | ﹤0.01% | 4644 |
|
|
2018
Q4 | $234K | Buy |
24,900
+8,200
| +49% | +$105K | ﹤0.01% | 7460 |
|
|
2018
Q3 | $316K | Sell |
16,700
-34,600
| -67% | -$664K | ﹤0.01% | 7387 |
|
|
2018
Q2 | $1M | Buy |
51,300
+15,200
| +42% | +$300K | ﹤0.01% | 5353 |
|
|
2018
Q1 | $678K | Sell |
36,100
-33,700
| -48% | -$728K | ﹤0.01% | 6027 |
|
|
2017
Q4 | $1.16M | Sell |
69,800
-32,400
| -32% | -$555K | ﹤0.01% | 4937 |
|
|
2017
Q3 | $2.1M | Buy |
+102,200
| New | +$1.15M | ﹤0.01% | 3807 |
|
Other funds holding VYGR
AC
VPC
VCM
OM
EAM
Susquehanna International Group's VYGR Position: Q1 2026 in Review
Susquehanna International Group increased its Voyager Therapeutics (VYGR) stake by 21% in Q1 2026, buying an estimated $54K and bringing the position to 78,891 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #10813.
Susquehanna International Group first reported a position in VYGR in Q4 2016 and has held it in 31 quarters since. The position peaked at $2.48M in Q1 2023. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.
- Susquehanna International Group held 78,891 shares of Voyager Therapeutics worth $305K as of Q1 2026.
- Susquehanna International Group bought 13,709 Voyager Therapeutics shares in Q1 2026, an estimated $54K.
- Voyager Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10813 holding.
- Susquehanna International Group first reported a position in Voyager Therapeutics in Q4 2016 and has held it in 31 quarters since.
- Susquehanna International Group's Voyager Therapeutics position peaked at $2.48M in Q1 2023.
- 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.